Ultragenyx Pharmaceutical Inc. (RARE) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 4 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 3, 2026after close 34 8-K
Q2 FY2026Tue, Aug 4, 2026after close 35 8-K
Q1 FY2026Tue, May 5, 2026after close 35 8-K
Q4 FY2025Thu, Feb 12, 2026after close 43 8-K
Q3 FY2025Tue, Nov 4, 2025after close 35 8-K
Q2 FY2025Tue, Aug 5, 2025after close 36 8-K
Q1 FY2025Tue, May 6, 2025after close 36 8-K
Q4 FY2024Thu, Feb 13, 2025after close 44 8-K

What they guided beta

Q3 FY2026 "EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers (PRVs) under agreement for combined sales price of $413 million Substantial reduction of expenses and hea" exhibit
Q3 FY2026 "NOVATO, Calif. – November 03, 2026 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2026, announced substantial expense reductions, and reaffirmed its guidance for 2026 revenue and 2027 profitability." exhibit
Q3 FY2026 "“With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”" exhibit
Q3 FY2026 "Third Quarter 2026 Revenue Highlights and 2026 Revenue Guidance" exhibit
Q3 FY2026 "The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from new product launches." exhibit
Read from the sentence: revenue $730 million to $760 million, FY2026
Q2 FY2026 "EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update Second quarter total revenue of $214 million, Crysvita® revenue of $156 million and Dojolvi® revenue of $27 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path to profitability in 2027 Catalysts in second half of 2026 include two PDUFA" exhibit
Q2 FY2026 "“In the second quarter we generated the highest quarterly revenue in the history of the company, supporting our full-year revenue guidance, and keeping us on track toward profitability in 2027,” said Emil D." exhibit
Q2 FY2026 "Second Quarter 2026 Revenue Highlights and 2026 Revenue Guidance" exhibit
Q2 FY2026 "The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from potential new product launches." exhibit
Read from the sentence: revenue $730 million to $760 million, FY2026
Q2 FY2026 "Crysvita revenue in the second quarter of 2026 was $156 million, consistent with expected seasonality in the U.S. and Canada and ordering patterns in Latin America." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RARE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RARE

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

RARE earnings date badge

HTML

<a href="https://veritasdata.dev/company/RARE/"><img src="https://veritasdata.dev/embed/RARE.svg" alt="RARE earnings date" width="240" height="56"></a>

Markdown

[![RARE earnings date](https://veritasdata.dev/embed/RARE.svg)](https://veritasdata.dev/company/RARE/)

Script

<script async src="https://veritasdata.dev/embed/RARE.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RARE"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.